Pharmacyclics® Triggers another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial Pharmacyclics, Inc. announced that the international, randomized phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a third $50 million milestone payment obligation from Janssen Biotech, Inc., worldwide collaborator on ibrutinib in oncology and sponsor of this trial. [Pharmacyclics, Inc.] Press Release
Recruit Top Talent:Reach more than 55,000 potential candidates bypostingyour organization’s career opportunities on the Connexon CreativeJob Board at no cost.
Have we missed an important article or publication in Hematopoiesis News? Click here to submit!